A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
An open-label multi-center phase Ib/II study to evaluate the efficacy and safety of
anti-PD-1/CTLA-4 bispecific antibody AK104 plus lenvatinib as the first-line therapy for
patients with advanced hepatocellular carcinoma.